CytomX Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
8analysts covering
FY Revenue (est.)
$25Mnext fiscal year
FY EPS (est.)
-$0.39next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Varseta-M Phase 1 Dose Optimization Data Update (CRC) | 31 Dec 2026 |
| Initial CX-801 + KEYTRUDA Phase 1 Combination Data in Melanoma | 31 Dec 2026 |
| Varseta-M Phase 1 Combination Study with Bevacizumab Initial Data | 30 Jun 2027 |
Monitoring Framework
Key Performance Indicators
Varseta-M (CX-2051) Confirmed Objective Response Rate (ORR) in CRC Quarterly3,200.0%Target: Maintain or exceed 20-32% ORR in registrational trials
Cash, Cash Equivalents, and Investments Quarterly346.7MTarget: Sufficient liquidity to fund operations into at least H2 2028
Total Quarterly Revenue Quarterly10.3MTarget: Stabilize and grow through new or expanded strategic collaborations
Watch Items
- Varseta-M Grade 3 Diarrhea and Toxicity ProfileTrigger: Incidence of Grade 3 diarrhea exceeding manageable levels despite updated prophylaxis and AIBW dosingAction: Re-evaluate dosing optimization, patient selection criteria, or prophylaxis protocols to protect the therapeutic window.
- CX-801 Combination Trial with KEYTRUDA (Pembrolizumab)Trigger: Initial clinical efficacy and safety data in advanced melanoma expected by end of 2026Action: Review clinical response rates and safety signals to determine advancement to Phase 2 expansion cohorts.
- FDA Alignment on Registrational Study for Varseta-MTrigger: Successful alignment with the FDA in 2026 on a potential registrational monotherapy study design in late-line CRCAction: Finalize trial protocol, initiate site activation, and prepare for patient enrollment by H1 2027.
Research as of 19 Jun 2026